Corbus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Clinical Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- FedEx pilots ratify new collective bargaining agreement
- The real reason Meta shares are surging has nothing to do with its new AI model
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
Corbus Pharma (CRBP) Misses Q4 EPS by 4c, Revenues Beat
March 12, 2019 7:10 AM EDTCorbus Pharma (NASDAQ: CRBP) reported Q4 EPS of ($0.30), $0.04 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $1.93 million versus the consensus estimate of $920 thousand.
Entered into strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. Deal included a $27 million upfront payment, up to $173 million of additional potential milestone payments and double-digit royalties;Appointed Craig Millian as Chief Commercial Officer to lead global marketing and commercialization... More